On Tuesday, Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) shares maintained a positive outlook as TD Cowen sustained its Buy rating and JPY46.00 price target on the company's stock.

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2 ...

Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd (OTC:DSNKY) and being jointly developed ...

Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of its investigational antibody-drug conjugate (ADC) DS-9606 for treating ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

In interviews with Fierce Pharma Marketing at Fierce’s annual Digital Pharma East event in Philadelphia last week, marketing leaders from Bayer, Daiichi Sankyo and argenx discussed that slower ...

Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards its goal of creating new standards of care for patients with cancer will include six late-breaking presentations, including two ...